Correction: The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta‑analysis
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
International journal of clinical pharmacy - 46(2024), 2 vom: 25. Jan., Seite 555-557 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cui, Yuying [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024 |
|---|
| doi: |
10.1007/s11096-023-01682-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055265472 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055265472 | ||
| 003 | DE-627 | ||
| 005 | 20240325060944.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11096-023-01682-x |2 doi | |
| 035 | |a (DE-627)SPR055265472 | ||
| 035 | |a (SPR)s11096-023-01682-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Cui, Yuying |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correction: The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta‑analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024 | ||
| 700 | 1 | |a Guo, Yingxue |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical pharmacy |d Springer International Publishing, 2011 |g 46(2024), 2 vom: 25. Jan., Seite 555-557 |h Online-Ressource |w (DE-627)SPR055265332 |w (DE-600)2601204-2 |w (DE-576)34126718X |x 2210-7711 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2024 |g number:2 |g day:25 |g month:01 |g pages:555-557 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11096-023-01682-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 936 | b | k | |a 44.40 |j Pharmazie |j Pharmazeutika |q VZ |
| 951 | |a AR | ||
| 952 | |d 46 |j 2024 |e 2 |b 25 |c 01 |h 555-557 | ||